Bioverativ Inc.'s two marketed hemophilia drugs, Eloctate and Alprolix, get most of the attention, but the blood disease specialist has been focused on diversifying beyond hemophilia in the year since it was spun out from Biogen.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?